Novartis: Remibrutinib Meets Primary Endpoints In Phase 3 Trials In RMS
Cuts RMS Relapse Rate By 35% Versus Rival - To Seek Global Approval For Remibrutinib In RMS
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.